Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial-Reference-Cited by-同舟云学术

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Published:2017-01 Issue:10064 Volume:389 Page:67-76
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Balar Arjun V,Galsky Matthew D,Rosenberg Jonathan E,Powles Thomas,Petrylak Daniel P,Bellmunt Joaquim,Loriot Yohann,Necchi Andrea,Hoffman-Censits Jean,Perez-Gracia Jose Luis,Dawson Nancy A,van der Heijden Michiel S,Dreicer Robert,Srinivas Sandy,Retz Margitta M,Joseph Richard W,Drakaki Alexandra,Vaishampayan Ulka N,Sridhar Srikala S,Quinn David I,Durán Ignacio,Shaffer David R,Eigl Bernhard J,Grivas Petros D,Yu Evan Y,Li Shi,Kadel Edward E,Boyd Zachary,Bourgon Richard,Hegde Priti S,Mariathasan Sanjeev,Thåström AnnChristine,Abidoye Oyewale O,Fine Gregg D,Bajorin Dean F

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study;Loehrer;J Clin Oncol,1992

2. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy;Galsky;J Clin Oncol,2011

3. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up;Bellmunt;Ann Oncol,2014

4. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1);De Santis;Ann Oncol,2016

Cited by 1811 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Radiotherapy as a Promising Alternative for Managing Advanced Upper Tract Urothelial Carcinoma: Rescuing Chemotherapy-Intolerant Patients;Clinical Genitourinary Cancer;2024-12

2. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor;Clinical Genitourinary Cancer;2024-12

3. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

4. Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases;Clinical Genitourinary Cancer;2024-10

5. Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin;Journal of Medical Economics;2024-09-11